ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month Low on Analyst Downgrade

ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after Guggenheim lowered their price target on the stock from $30.00 to $28.00. Guggenheim currently has a buy rating on the stock. ArriVent BioPharma traded as low as $10.91 and last traded at $10.96, with a volume of 92,698 shares trading hands. The stock had previously closed at $11.56.

Several other analysts have also recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $29.00 price target on shares of ArriVent BioPharma in a report on Friday, October 16th. Truist Financial upped their price objective on shares of ArriVent BioPharma from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ArriVent BioPharma in a research report on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $25.00 target price on shares of ArriVent BioPharma in a research note on Monday, October 26th. Finally, Citigroup reduced their price target on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.67.

View Our Latest Stock Analysis on ArriVent BioPharma

Institutional Investors Weigh In On ArriVent BioPharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in shares of ArriVent BioPharma by 29.7% during the third quarter. Goldman Sachs Group Inc. now owns 1,107,094 shares of the company’s stock valued at $33,523,000 after purchasing an additional 253,371 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of ArriVent BioPharma during the third quarter valued at approximately $478,000. Jump Financial LLC lifted its holdings in shares of ArriVent BioPharma by 173.5% during the third quarter. Jump Financial LLC now owns 81,067 shares of the company’s stock valued at $2,455,000 after purchasing an additional 51,423 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of ArriVent BioPharma by 38.7% in the 3rd quarter. Alps Advisors Inc. now owns 65,315 shares of the company’s stock worth $1,978,000 after purchasing an additional 18,241 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of ArriVent BioPharma in the 3rd quarter worth approximately $76,000. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Stock Performance

The business has a 50-day moving average price of $20.97 and a 200 day moving average price of $26.35. The stock has a market capitalization of $577.71 million, a P/E ratio of -3.10 and a beta of 1.66.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, research analysts forecast that ArriVent BioPharma, Inc. will post -3.81 earnings per share for the current fiscal year.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

See Also

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.